Research article · 15 Apr 2026
Conference abstractPublished 20 Aug 2012
Immunotherapy of renal cell cancer: The efficacy and challenges
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
A doptive transfer of tumor reactive lymphoid cells has been one of the effective immunotherapies for eradicating advanced tumor burdens. We reported a phase II trial where patients with stage IV renal cell cancer (RCC) were vaccinated with irradiated autologous tumor cells admixed with BCG to induce vaccine-primed lymph nodes (VPLN). Lymphoid cells harvested from VPLN were secondarily activated in vitro, and were subsequently infused intravenously into the patients along with the concomitant administration of IL-2. Among the 34 evaluable patients who completed an initial course of cell therapy, there were 9 responses (27%). Overall survival of responders was significantly prolonged compared to non-responders (p<0.001). While the administration of in vivo primed and in vitro activated VPLN cells and IL-2 resulted in durable tumor responses in patients with advanced renal cell cancer, further improvements in therapy are needed. The inability to target cancer stem cells (CSC) with current immune approaches may be a significant factor for treatment failures. We recently identified CSC- enriched populations in two murine tumors (melanoma D5 and squamous cell cancer SCC7). Enriched cancer stem cells are immunogenic and significantly more effective as an antigen source compared with unselected tumor cells in inducing protective anti-tumor immunity. We found that selective targeting of cancer stem cells by CSC-primed antibodies and T cells represented the mechanisms involved in CSC vaccine-conferred anti-tumor immunity. Identifying and targeting cancer stem cells in renal cell cancer may lead to the development of more potent immunological approaches for therapy.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Qiao Li”
